Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications. Issue 6 (19th November 2019)

• Record Type: Journal Article
• Authors: Wu, Rongzhen; Chen, Hongyu; Chang, Ninghui; Xu, Yuzhi; Jiao, Jiao; Zhang, Hailong
• Is Part Of: Chemistry. Volume 26:Issue 6(2020)
• Page Start: 1166
• Page End: 1195
• Publication Date: 2019-11-19
• Subjects: antitumor agents -- bioactivity -- bryostatins -- drug discovery -- total synthesis; Chemistry -- Periodicals; 540
• DOI: 10.1002/chem.201903128
• Languages: English
• ISSNs: 0947-6539

Abstract

Abstract: Bryostatins are a class of naturally occurring macrocyclic lactones with a unique fast developing portfolio of clinical applications, including treatment of AIDS, Alzheimer's disease, and cancer. This comprehensive account summarizes the recent progress (2014–present) in the development of bryostatins, including their total synthesis and biomedical applications. An emphasis is placed on the discussion of bryostatin 1, the most‐studied analogue to date. This review highlights the synthetic and biological challenges of bryostatins and provides an outlook on their future development. Abstract : Promising candidates : The development of bryostatins, a class of naturally occurring macrocyclic lactones, which might find application in the treatment of, for example, AIDS, Alzheimer's disease, and cancer is summarized, focusing on recent work on their total synthesis and biomedical applications.